SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Entrada Therapeutics, Inc. (NASDAQ:TRDA). The investigation focuses on Entrada's executive officers and whether investor losses may be recovered under federal securities laws.
What if I purchased Entrada securities?
If you purchased Entrada securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.
Or for more information, contact Jim Baker at [email protected] or (619) 814-4471.
There is no cost or obligation to you.
Background of the investigation
On May 7, 2026, Entrada announced topline results from Cohort 1 of the Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601-44 in participants with Duchenne muscular ...